GLP-1 RAs for Treating Metabolic Dysfunction-Associated Steatosis Liver Disease: From GLP-1 Discovery to FDA Approval: A Comprehensive Narrative Review - PubMed
6 hours ago
- #GLP-1RAs
- #MASLD
- #FDA Approval
- MASLD is now the most common chronic liver disease globally, with no approved pharmacological treatments for many years, leaving lifestyle changes and weight loss as the primary interventions.
- GLP-1RAs, originally developed for type 2 diabetes and obesity, have gained FDA approval for MASLD, showing efficacy in reducing liver fat, inflammation, and disease progression.
- This review synthesizes evidence from in vitro models, animal studies, and clinical trials, while discussing current limitations and future research directions for GLP-1RAs in MASLD.